BioCentury
ARTICLE | Strategy

Jump-starting growth

Analyzing Celgene’s growth prospects after Juno, Impact deals

January 27, 2018 5:42 AM UTC

Celgene Corp.’s two deals this month -- including its largest ever acquisition, of Juno Therapeutics Inc. -- will help fill in the holes left by late-stage failures and commercial disappointments of candidates that were intended to replace lost revenues after Revlimid lenalidomide loses patent protection.

If Celgene can navigate the clinical and commercial risks associated with Juno’s pipeline and execute on its own late-stage candidates, the company could see revenue growth accelerate through the mid-2020s...